This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Dahlberg L, Lindman H, Lundkvist J.A cohort study of the total health care costs for modern treatment of disseminated breast cancer. Breast Cancer Research and Treatment 106 (Suppl. 1): 105 (plus poster) abstr. 2062, Dec 2007
Karnon J, Ditrapani F, Kaura S.Cost-effectiveness of late extended adjuvant letrozole following a prolonged therapy break from tamoxifen - MA-17 post-unblinding analysis. Breast Cancer Research and Treatment 106 (Suppl. 1): 104 (plus poster) abstr. 2058, Dec 2007
El Ouagari K, Karnon J, Kaura S.Comparison of cost of distant diseae-free year gained of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective. Breast Cancer Research and Treatment 106 (Suppl. 1): 104 (plus poster) abstr. 2059, Dec 2007
Rights and permissions
About this article
Cite this article
Letrozole leads the way in the treatment of breast cancer. Pharmacoecon. Outcomes News 544, 3–4 (2008). https://doi.org/10.2165/00151234-200805440-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805440-00005